{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:45:37Z","timestamp":1790840737706,"version":"4.1.0"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"10","funder":[{"name":"Dipartimento di Scienze della Salute - Universit\u00e0 degli Studi di Milano","award":["PSR 2015\u20132017- Linea 2"],"award-info":[{"award-number":["PSR 2015\u20132017- Linea 2"]}]},{"name":"Fondazione Carlo Erba in collaboration with Kedrion Biopharma","award":["Guelfo Marcucci-2017"],"award-info":[{"award-number":["Guelfo Marcucci-2017"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Essential thrombocythemia (ET) patients are treated with aspirin (acetylsalicylic acid [ASA]) to prevent thrombosis. Previous studies showed that serum thromboxane (Tx) B2 was high 24\u2009hours after enteric-coated (EC)-ASA in ET patients, due to increased number of noninhibited reticulated platelets (RPs), consequent to high platelet turnover, and that ASA should be given twice a day to ET patients. We studied ET patients (n\u2009=\u200917) and healthy subjects (n\u2009=\u200910) on 100\u2009mg EC-ASA once daily; experiments were repeated after 14-day treatment with 100\u2009mg plain-ASA once daily. Serum TxB2, plasma ASA, and salicylic acid (SA) were measured before the morning dose and up to 8\u2009hours thereafter. Blood activity of ASA-deacethylating esterases, in vitro inhibition of collagen-induced TxB2 production by ASA (10\u20131,000 \u00b5M), and number of RP were measured. TxB2 inhibition by ASA in vitro and esterases activities were normal in all subjects. EC-ASA elicited highly variable responses; 6 ET patients were poor responders, as their serum TxB2 was high after EC-ASA; their plasma levels of ASA and SA were low\/undetectable. In contrast to EC-ASA, plain ASA decreased serum TxB2 and increased plasma ASA and SA in all subjects. Serum TxB2 was high in ET patients at 24\u2009hours and significantly correlated with RP count (but not RP percentage) and platelet count. Plain ASA should be used in ET patients to inhibit platelets efficiently. The identification of ET patients who might benefit from twice a day ASA could simply be based on their platelet count: since their platelet turnover is not increased, ET patients with normalized platelet count should not need twice a day ASA treatment.<\/jats:p>","DOI":"10.1055\/s-0040-1714351","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T23:20:35Z","timestamp":1595892035000},"page":"1442-1453","source":"Crossref","is-referenced-by-count":12,"title":["Patients with Essential Thrombocythemia may be Poor Responders to Enteric-Coated Aspirin, but not to Plain Aspirin"],"prefix":"10.1055","volume":"120","author":[{"given":"Mariangela","family":"Scavone","sequence":"first","affiliation":[{"name":"Laboratory of Hemostasis and Thrombosis, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milan, Milan, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rizzo","sequence":"first","affiliation":[{"name":"Clinical Biochemistry and Mass Spectrometry, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milan, Milan, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eti A.","family":"Femia","sequence":"additional","affiliation":[{"name":"Laboratory of Hemostasis and Thrombosis, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milan, Milan, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Podda","sequence":"additional","affiliation":[{"name":"Laboratory of Hemostasis and Thrombosis, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milan, Milan, Lombardia, Italy"},{"name":"Unit\u00e0 di Medicina, ASST Santi Paolo e Carlo, Ospedale San Paolo, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bossi","sequence":"additional","affiliation":[{"name":"Laboratory of Hemostasis and Thrombosis, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milan, Milan, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Caberlon","sequence":"additional","affiliation":[{"name":"Unit\u00e0 di Medicina, ASST Santi Paolo e Carlo, Ospedale San Paolo, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Paroni","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry and Mass Spectrometry, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milan, Milan, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Laboratory of Hemostasis and Thrombosis, Dipartimento di Scienze della Salute, Universit\u00e0 degli Studi di Milan, Milan, Lombardia, Italy"},{"name":"Unit\u00e0 di Medicina, ASST Santi Paolo e Carlo, Ospedale San Paolo, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"20","key":"ref1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/blood-2016-05-643346","article-title":"How I treat essential thrombocythemia","volume":"128","author":"E Rumi","year":"2016","journal-title":"Blood"},{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study","volume":"168","author":"M Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"issue":"05","key":"ref3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"T Barbui","year":"2018","journal-title":"Leukemia"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm 2018","volume":"8","author":"A Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"22","key":"ref5","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"A Tefferi","year":"2019","journal-title":"N Engl J Med"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-949664","article-title":"The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera","volume":"32","author":"J J Michiels","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref7","first-page":"894","article-title":"Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders","volume":"103","author":"T W Malpass","year":"1984","journal-title":"J Lab Clin Med"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/s-0038-1666917","article-title":"Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder","volume":"42","author":"F Rendu","year":"1979","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0049-3848(84)90019-7","article-title":"Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders","volume":"33","author":"S S Swart","year":"1984","journal-title":"Thromb Res"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/09537104.2019.1584668","article-title":"Evaluation of platelet function in essential thrombocythemia under different analytical conditions","volume":"31","author":"F Lussana","year":"2020","journal-title":"Platelets"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000360388","article-title":"Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera","volume":"133","author":"J J Michiels","year":"2015","journal-title":"Acta Haematol"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera","volume":"33","author":"A Falanga","year":"2005","journal-title":"Exp Hematol"},{"issue":"02","key":"ref13","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"E Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2011-02-337337","article-title":"Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia","volume":"118","author":"N Maugeri","year":"2011","journal-title":"Blood"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"A Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"F Lussana","year":"2009","journal-title":"Thromb Res"},{"issue":"25","key":"ref17","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"T Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"ref18","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"J Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"E M Boyd","year":"2010","journal-title":"Br J Haematol"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia","volume":"74","author":"B Rocca","year":"1995","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref21","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","article-title":"Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo","volume":"80","author":"R Landolfi","year":"1992","journal-title":"Blood"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"R Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"22","key":"ref23","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"C Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"22","key":"ref24","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative Neoplasms","volume":"376","author":"J L Spivak","year":"2017","journal-title":"N Engl J Med"},{"issue":"03","key":"ref25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.leukres.2010.10.009","article-title":"Aspirin in low-risk essential thrombocythemia, not so simple after all?","volume":"35","author":"C Harrison","year":"2011","journal-title":"Leuk Res"},{"issue":"25","key":"ref26","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","article-title":"Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance","volume":"113","author":"A L Frelinger III","year":"2006","journal-title":"Circulation"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2009-08-236679","article-title":"The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy","volume":"115","author":"A Dragani","year":"2010","journal-title":"Blood"},{"issue":"15","key":"ref28","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"S Pascale","year":"2012","journal-title":"Blood"},{"issue":"08","key":"ref29","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1161\/01.STR.0000231683.43347.ec","article-title":"Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers","volume":"37","author":"D Cox","year":"2006","journal-title":"Stroke"},{"issue":"07","key":"ref30","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","article-title":"Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease","volume":"46","author":"A O Maree","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"T Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/leu.2011.306","article-title":"How to manage essential thrombocythemia","volume":"26","author":"G Finazzi","year":"2012","journal-title":"Leukemia"},{"issue":"02","key":"ref33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF02599986","article-title":"Examiner dependence on physical diagnostic tests for the detection of splenomegaly: a prospective study with multiple observers","volume":"8","author":"S G Tamayo","year":"1993","journal-title":"J Gen Intern Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.microc.2016.11.005","article-title":"Robust and sensitive LC\/MS-MS method for simultaneous detection of acetylsalicylic acid and salicylic acid in human plasma","volume":"136","author":"D Sirok","year":"2018","journal-title":"Microchem J"},{"issue":"17","key":"ref35","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1074\/jbc.M112.427674","article-title":"Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2)","volume":"288","author":"G Zhou","year":"2013","journal-title":"J Biol Chem"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.2019004596","article-title":"A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia","volume":"136","author":"B Rocca","year":"2020","journal-title":"Blood"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/jth.14445","article-title":"Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation","volume":"17","author":"G Petrucci","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1080\/09537104.2019.1667495","article-title":"Weight as an assay-independent predictor of poor response to enteric aspirin in cardiovascular patients","volume":"31","author":"M McCall","year":"2020","journal-title":"Platelets"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/j.1538-7836.2010.03997.x","article-title":"The role of weight and enteric coating on aspirin response in cardiovascular patients","volume":"8","author":"A Peace","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2016.11.050","article-title":"Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus","volume":"69","author":"D L Bhatt","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(96)01254-8","article-title":"Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product","volume":"348","author":"J P Kelly","year":"1996","journal-title":"Lancet"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1714351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T01:57:59Z","timestamp":1600912679000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1714351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,9,23]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1714351","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]}}}